Volume 5 – Number 2 – July 2019

Left ventricular dysfunction before transcatheter aortic valve implantation

Kentaro Hayashida*, MD, PhD, FESC, FACC, FJCS
AsiaIntervention 2019;5:110-111, DOI: 10.4244/AIJV5I2A18

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan

Transcatheter aortic valve implantation (TAVI) has already been established as a viable treatment option for most patients with aortic stenosis. However, left ventricular (LV) systolic dysfunction still remains one of the risk factors for procedural difficulty and poor clinical outcomes.

In this issue of AsiaIntervention, Soon et al report the improvement of LV function after TAVI in 662 patients and identify more severe LV systolic dysfunction as an independent predictor of LV recovery. Among patients with severe LV dysfunction (left ventricular ejection fraction [LVEF] <30%), frailty and male gender were identified as independent predictors of LV recovery.

Although these findings are in line with those from the PARTNER trial1, as the authors describe, poor baseline LV function may be associated with worse survival after TAVI. The conclusions from this analysis may suggest that severe LV dysfunction is associated with poor outcomes but also with improvement of LV recovery. One of the most important messages from this study is that the majority of patients with severe LV dysfunction showed LV improvement after TAVI; therefore, TAVI should not be avoided because of the presence of LV dysfunction. Indeed, recent studies have demonstrated excellent midterm clinical outcome after TAVI. The OCEAN-TAVI Japanese multicenter registry demonstrated overall 30-day mortality and cumulative 1-year mortality to be 1.7% and 11.3%, respectively2; most of the patients had non-cardiac death during follow-up. These data suggest that most patients had sufficient clinical benefit after TAVI even with concomitant LV dysfunction. The reason for this finding is unclear; however, the less invasive nature of this procedure could maximise survival benefit by minimising periprocedural complications and death. It was also interesting to see that improvement of LV did not have an impact on late mortality by Kaplain-Meier survival analysis in this study. The lack of a sufficient number of events could be the reason for this finding. Further studies comparing TAVI and surgical aortic valve replacement (SAVR) could be of great interest. The authors also demonstrated that female gender was identified as a predictor of good LV recovery. Female gender is known to lead to better survival after TAVI3; better LV recovery could be one of the reasons for this.

Concomitant aortic stenosis and mitral regurgitation is also a challenging situation. The current ESC/EACTS guidelines identified that mitral disease is one of the favourable factors for choosing a surgical procedure over TAVI4. However, improvement of mitral regurgitation after TAVI is sometimes found, especially in case of functional mitral regurgitation with the mechanism of tethering5,6. If we could predict LV recovery accurately, this would have an impact on an appropriate selection strategy for patients with aortic stenosis and concomitant mitral regurgitation.

In line with the rapid progress and improvement of TAVI, clinical data after this procedure are improving year by year. This study provides an encouraging message to treat patients with poor LV function. Further studies are needed to clarify this important issue.

Conflict of interest statement
K. Hayashida is a clinical proctor for Edwards Lifesciences.

1. Soon KH, Kooistra NHM, Voskuil M, Kraaijeveld AO, Stella PR. LV systolic dysfunction stands to gain the most post transcatheter aortic valve implantation (TAVI). AsiaIntervention. 2019;5:142-8.
2. Elmariah S, Palacios IF, McAndrew T, Hueter I, Inglessis I, Baker JN, Kodali S, Leon MB, Svensson L, Pibarot P, Douglas PS, Fearon WF, Kirtane AJ, Maniar HS, Passeri JJ; PARTNER Investigators. Outcomes of transcatheter and surgical aortic valve replacement in high-risk patients with aortic stenosis and left ventricular dysfunction: results from the Placement of Aortic Transcatheter Valves (PARTNER) trial (cohort A). Circ Cardiovasc Interv. 2013;6:604-14.
3. Yamamoto M, Watanabe Y, Tada N, Naganuma T, Araki M, Yamanaka F, Mizutani K, Tabata M, Ueno H, Takagi K, Higashimori A, Shirai S, Hayashida K; OCEAN-TAVI investigators. Transcatheter aortic valve replacement outcomes in Japan: Optimized CathEter vAlvular iNtervention (OCEAN) Japanese multicenter registry. Cardiovasc Revasc Med. 2018 Dec 4. [Epub ahead of print].
4. Hayashida K, Morice MC, Chevalier B, Hovasse T, Romano M, Garot P, Farge A, Donzeau-Gouge P, Bouvier E, Cormier B, Lefèvre T. Sex-related differences in clinical presentation and outcome of transcatheter aortic valve implantation for severe aortic stenosis. J Am Coll Cardiol. 2012;59:566-71.
5. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739-86.
6. Bedogni F, Latib A, De Marco F, Agnifili M, Oreglia J, Pizzocri S, Latini RA, Lanotte S, Petronio AS, De Carlo M, Ettori F, Fiorina C, Poli A, Cirri S, De Servi S, Ramondo A, Tarantini G, Marzocchi A, Fiorilli R, Klugmann S, Ussia GP, Tamburino C, Maisano F, Brambilla N, Colombo A, Testa L. Interplay between mitral regurgitation and transcatheter aortic valve replacement with the CoreValve Revalving System: a multicenter registry. Circulation. 2013;128:2145-53.

To download, please click below.


Volume 5 - Number 2 - July 2019

View full issue